Bupropion hydrochloride (XL)
- Product NDC
- 70518-1229
- 11-digit product format
- 705181229
- Labeler code
- 70518
- Product ID
- 70518-1229_de1cf9ab-31f3-4638-e053-2995a90a61ae
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Bupropion hydrochloride
- Dosage form
- TABLET, EXTENDED RELEASE
- Route
- ORAL
- Labeler
- REMEDYREPACK INC.
- Application
- ANDA208652
- Marketing category
- ANDA
- Marketing start
- 2018-05-25
- Marketing end
- 0000-00-00
- Substance
- BUPROPION HYDROCHLORIDE
- Active strength
- 300 mg/1
- Pharmacologic classes
- Aminoketone [EPC], Dopamine Uptake Inhibitors [MoA], Increased Dopamine Activity [PE], Increased Norepinephrine Activity [PE], Norepinephrine Uptake Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2023-12-31
- Current FDA listing
- Historical FDA.report record
NDC auxiliary status#
Explicit status records from FDA unfinished, excluded, and compounder auxiliary files. Absence of a row is not itself a regulatory status. Browse every current auxiliary row, including rows without a usable NDC. · Browse every captured source and parsed snapshot.
| Dataset | Scope | Product NDC | Package NDC | Code | Status | Reporting period | Source date |
|---|---|---|---|---|---|---|---|
| excluded product | product | 70518-1229 | D | Discontinued by firm | 2026-07-31 | ||
| excluded package | package | 70518-1229 | 70518-1229-0 | D | Discontinued by firm | 2026-07-31 | |
| excluded package | package | 70518-1229 | 70518-1229-1 | D | Discontinued by firm | 2026-07-31 |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A208652-001 | BUPROPION HYDROCHLORIDE | BUPROPION HYDROCHLORIDE | 150MG | TABLET, EXTENDED RELEASE / ORAL | AB3 | 2017-08-21 | |
| A208652-002 | BUPROPION HYDROCHLORIDE | BUPROPION HYDROCHLORIDE | 300MG | TABLET, EXTENDED RELEASE / ORAL | AB3 | 2017-08-21 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A208652-001 | AB3 |
| A208652-002 | AB3 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A208652-001 | BUPROPION HYDROCHLORIDE | 150MG | TABLET, EXTENDED RELEASE / ORAL | AB3 | 2017-08-21 | a50c72e98297… | |
| 2026-08-01 22:54:32 | 2026-06 | A208652-002 | BUPROPION HYDROCHLORIDE | 300MG | TABLET, EXTENDED RELEASE / ORAL | AB3 | 2017-08-21 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-01 22:54:32 | 2026-06 | A208652-001 | AB3 | 1 | a50c72e98297… |
| 2026-08-01 22:54:32 | 2026-06 | A208652-002 | AB3 | 1 | a50c72e98297… |
openFDA label cross-check#
Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Bupropion Hydrochloride (XL) | BUPROPION HYDROCHLORIDE | Mullan Pharmaceutical Inc. | 75b1e027-4c5d-46e5-98ee-033e67bd411c | 2026-01-29 | Boxed warning, Warnings, Adverse reactions | 208652 ANDA208652 |
| Bupropion hydrochloride (XL) | BUPROPION HYDROCHLORIDE | Lannett Company Inc. | 15c4e95a-d203-4caf-b6c7-44792355cb76 | 2025-12-31 | Boxed warning, Warnings, Adverse reactions | 208652 ANDA208652 |
| Bupropion hydrochloride (XL) | BUPROPION HYDROCHLORIDE | Vitruvias Therapeutics | f53704b2-3d3c-47e8-9fd6-a0f5240c0593 | 2025-12-31 | Boxed warning, Warnings, Adverse reactions | 208652 ANDA208652 |
| BUPROPION HYDROCHLORIDE (XL) | BUPROPION HYDROCHLORIDE (XL) | Chartwell RX, LLC | 8d9779e7-300e-4720-8ba5-2272b2506cd9 | 2024-04-05 | Boxed warning, Warnings, Adverse reactions | 208652 ANDA208652 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|
| 70518-1229-0 | 70518122900 | 30 TABLET, EXTENDED RELEASE in 1 BLISTER PACK (70518-1229-0) | 2018-05-25 | 0000-00-00 | No | No | Current |